NeuroSense Therapeutics Ltd. Ordinary Shares
Symbol: NRSN (NASDAQ)
1.40
▲ (20.00%) 0.234
Company Description:
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Key Stats
- Today's Open: $1.1599
- Today's High: $1.961
- Today's Low: $1.125
- Today's Volume: 15.47M
- Yesterday Close: $1.17
- Yesterday High: $1.17
- Yesterday Low: $1.1
- Yesterday Volume: 67.83K
- Last Min Volume: 246.62K
- Last Min High: $1.435
- Last Min Low: $1.383
- Last Min VWAP: $1.40936
Company Profile
- Name: NeuroSense Therapeutics Ltd. Ordinary Shares
- Website: https://www.neurosense-tx.com
- Listed Date: 2021-12-09
- Location: ,
- Market Status: Active
- CIK Number: 0001875091
- SIC Code:
- SIC description:
- Market Cap: $29.05M
- Round Lot: 100
- Outstanding Shares: 25.04M
- Asset Type: CS
RECENT FILINGS FOR NRSN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 6-K | View |
| 2025-09-04 | 6-K | View |
| 2025-09-04 | 6-K | View |
| 2025-09-02 | 6-K | View |
| 2025-08-21 | 6-K | View |
| 2025-08-20 | 6-K | View |
| 2025-08-18 | EFFECT | View |
| 2025-08-18 | EFFECT | View |
| 2025-08-15 | S-8 | View |
| 2025-08-15 | POS AM | View |
| 2025-08-15 | POS AM | View |
| 2025-08-08 | 424B5 | View |
| 2025-08-01 | 6-K | View |
| 2025-07-10 | 6-K | View |
| 2025-06-26 | 6-K | View |
| 2025-05-07 | 6-K | View |
| 2025-04-24 | 6-K | View |
| 2025-04-16 | EFFECT | View |
| 2025-04-16 | EFFECT | View |
| 2025-04-11 | POS AM | View |
Latest News on NRSN